Validation of computed tomographic lung densitometry for monitoring emphysema in α1-antitrypsin deficiency

Background: Lung densitometry derived from computed tomographic images offers an opportunity to quantify emphysema non-invasively, but a pathological standard cannot be applied to validate its use in longitudinal monitoring studies. Consequently, forced expiratory volume in 1 second (FEV1) remains the standard against which new methods must be judged. We related progression of densitometry (15th percentile point and voxel index, threshold −950 Hounsfield units) to disease stage and FEV1 decline in two studies of subjects with α1-antitrypsin deficiency (PiZ). Methods: Consistency of progression, measured using densitometry and FEV1, was assessed in relation to disease stage in a 2 year study of 74 subjects grouped according to the FEV1 criteria employed in the GOLD guidelines. In the second study of a subgroup of subjects with extended data (n = 34), summary statistics were applied to measurements performed annually over 3 years and the rate of progression of densitometry was related to FEV1 decline. Results: The progression of percentile point was consistent across a wide spectrum of disease severity, but voxel index progression varied in association with disease stage (p = 0.004). In the second study, FEV1 decline correlated with progression of lung densitometry (percentile point: rS = 0.527, p = 0.001; voxel index: rS = −0.398, p = 0.012). Conclusions: 15th percentile point is a more consistent measure of lung density loss across a wide range of physiological impairment than voxel index. However, both methods are valid for use in longitudinal and interventional studies in which emphysema is the major outcome target.

[1]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[2]  The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. , 1985, The American review of respiratory disease.

[3]  R. Stockley,et al.  Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. , 2001, American journal of respiratory and critical care medicine.

[4]  A. Dirksen,et al.  Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT. , 1997, Acta radiologica.

[5]  J. Hogg,et al.  Report of a workshop: quantitative computed tomography scanning in longitudinal studies of emphysema , 2004, European Respiratory Journal.

[6]  Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. , 1994, Respiratory medicine.

[7]  B. Stoel,et al.  α1-Antitrypsin deficiency · 7: Computed tomographic imaging in α1-antitrypsin deficiency , 2004, Thorax.

[8]  H A Vrooman,et al.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.

[9]  W. Thurlbeck.  Measurement of pulmonary emphysema. , 1967, The American review of respiratory disease.

[10]  A. E. Anderson,et al.  Topology of nonrespiratory bronchioles of normal and emphysematous lungs. , 1974, Human pathology.

[11]  D. Postma,et al.  Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[12]  A. Buist,et al.  The natural history of air-flow obstruction in PiZ emphysema. Report of an NHLBI workshop. , 1983, The American review of respiratory disease.

[13]  J. Best,et al.  DIAGNOSIS OF PULMONARY EMPHYSEMA BY COMPUTERISED TOMOGRAPHY , 1984, The Lancet.

[14]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[15]  R. Stockley,et al.  Exercise capacity predicts health status in α1-Antitrypsin deficiency , 2001 .

[16]  T. Beaty,et al.  Risk factors associated with longitudinal change in pulmonary function. , 2015, The American review of respiratory disease.

[17]  B. Stoel,et al.  Repeatability of Lung Density Measurements with Low-Dose Computed Tomography in Subjects with &agr;-1-Antitrypsin Deficiency–Associated Emphysema , 2001, Investigative radiology.

[18]  E. Piitulainen,et al.  Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). , 1999, The European respiratory journal.

[19]  E. Hoffman,et al.  Assessment of the pulmonary structure-function relationship and clinical outcomes measures: quantitative volumetric CT of the lung. , 1997, Academic radiology.

[20]  M. Lebowitz,et al.  Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. , 1987, The American review of respiratory disease.

[21]  R. Bossé,et al.  Longitudinal effect of age and smoking cessation on pulmonary function. , 2015, The American review of respiratory disease.

[22]  H Putter,et al.  Correlation between annual change in health status and computer tomography derived lung density in subjects with α1-antitrypsin deficiency , 2003, Thorax.

[23]  P De Vuyst,et al.  Comparison of computed density and macroscopic morphometry in pulmonary emphysema. , 1995, American journal of respiratory and critical care medicine.

[24]  B Suki,et al.  Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Stockley,et al.  Exercise capacity predicts health status in alpha(1)-antitrypsin deficiency. , 2001, American journal of respiratory and critical care medicine.

[26]  Thurlbeck Wm.  Measurement of pulmonary emphysema. , 1967 .

[27]  J. Hogg,et al.  Site and nature of airway obstruction in chronic obstructive lung disease. , 1968, The New England journal of medicine.

[28]  Lene Theil Skovgaard,et al.  Progress of emphysema in severe α1-Antitrypsin Deficiency as Assessed by Annual CT , 1997 .

[29]  Jan Stolk,et al.  Influence of calibration on densitometric studies of emphysema progression using computed tomography. , 2004, American journal of respiratory and critical care medicine.

[30]  E. Hoffman,et al.  Interstitial lung disease: A quantitative study using the adaptive multiple feature method. , 1999, American journal of respiratory and critical care medicine.

[31]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[32]  Jc,et al.  Terminology, Definitions, and Classification of Chronic Pulmonary Emphysema and Related Conditions , 1959 .

[33]  Jan Stolk,et al.  Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. , 2004, American journal of respiratory and critical care medicine.

[34]  B. Burrows,et al.  Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. , 1969, The New England journal of medicine.

[35]  F. Speizer,et al.  The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. , 1988, The American review of respiratory disease.

[36]  J. Best,et al.  CT measurements of lung density in life can quantitate distal airspace enlargement--an essential defining feature of human emphysema. , 1988, The American review of respiratory disease.

[37]  N. Müller,et al.  "Density mask". An objective method to quantitate emphysema using computed tomography. , 1988, Chest.

[38]  P De Vuyst,et al.  Comparison of computed density and microscopic morphometry in pulmonary emphysema. , 1996, American journal of respiratory and critical care medicine.

[39]  Physiologists.  Guidelines for the measurement of respiratory function , 1994 .

[40]  R. Stockley,et al.  Predictors of mortality in α1-antitrypsin deficiency , 2003, Thorax.